Oncologist focus on GI tumors. Biliary-pancreatic& gastroesophaguesl tumors in @hospitaldelmar @HMar_research.
Joined July 2011
- Tweets6.6K
- Following714
- Followers436
- Likes4.6K
lvisa retweeted
Analytical and clinical comparison of three PD-L1 antibody clones using Tumor Area Positivity (TAP) and Combined Positive Score (CPS) scoring in advanced gastric cancer
link.springer.com/article/10…
lvisa retweeted
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies.
In @LancetGastroHep, a Review evaluates the clinical development of therapeutic cancer vaccines in PDAC: spkl.io/60107kQ3K
ALT Antigen sources and vaccine platforms in PDAC. Created in BioRender. Chap, B. S. (2026) https://BioRender.com/7xdlrqt. (A) Patient-derived tumour tissue can provide multiple antigen sources, including whole-tumour lysate, TAAs, TSAs, and neoantigens. These antigens undergo selection and, when applicable, computation epitope prediction to prioritise immunogenic targets, which are subsequently incorporated into a final vaccine formulation. (B) Several vaccine platforms are being explored in PDAC, including cell-based and dendritic cell-based vaccines, mRNA-based and DNA-based vaccines, peptide and protein vaccines, and microorganism-based approaches, all aiming to induce tumour-specific T-cell responses against the pancreatic tumour.
lvisa retweeted
ESMO 2026 - pancreatic cancer, all you need to know.
1) KRAS is finally druggable, which slammed the door open for a new era in treating this disease. This week, two drugs added to chemotherapy shrank tumors in 63–87% of patients, not just stabilization, numbers nobody has seen in this disease.
xitter.gq/yannickbuccella/status…
2) And one moved to where cure lives. Given before surgery, 97% of patients reached the operating table and every operation removed the tumor completely. Add immunotherapy to the mix and we might increase efficacy further.
xitter.gq/yannickbuccella/status…
Caveats throughout: early-phase, small, survival data immature, much of it from single countries. But this means progress never seen in treating this disease.
3) Daraxonrasib was the very first drug to revolutionize pancreatic cancer care and we continue to learn. Very early data seem to indicate a better efficacy of daraxonrasib with KRAS-G12V mutations rather than the more common G12D. Which in turn makes combinations with a dedicated G12D inhibitor like zoldonrasib very promising. Data pending, we should know more next year.
xitter.gq/yannickbuccella/status…
KRAS inhibitors strike once again: A pancreatic cancer combination just reported a 75% response rate in the untreated metastatic setting.
In a disease where 25-30% has been the ceiling for decades or forever.
This trial added a KRAS-G12D inhibitor - which is the most common KRAS variant - to standard chemotherapy in 50 patients: tumors shrank in 62.5% with a 2 chemo-drug-regimen, 75% with a 3-chemo-drug-regimen. In that second group, every patient's disease was at least held in check.
Still after all that daraxonrasib hype, those are mindblowing numbers. Absolutely unprecedented.
A bigger study in the same setting is currently running, I have already included patients there myself. Let’s see the final results of that, but they will be similar in my opinion.
Exciting times in pancreatic cancer care!
lvisa retweeted
CLARITY- Gastric 01 (CG-01) Phase III AZD-0901 (Sone-Ve) in 2L+ met #Claudin 18.2 (+) in #Gastroesophageal #cancer vs. investigators choice (N=594)
Primary endpoints: PFS + OS
🔹OS: 10M vs. 5M (HR = 0.47) 👏
🔹12M OS: 38.1% vs. 18.1%, HR = 0.47 (3rd line)
🔹 12M 42.6% in 2nd line
🔹 ORR: 23.3% vs. 13.8%
🔹PFS: HR = 0.77 was NS in 2L+
🔹PFS: HR = 4.1 vs. 2.7M; HR = 0.56 in 3L+
🔹Need more data in the 2L setting; largest benefit seen in 3L+ setting
#ESMO2026 @OncoAlert #cancerresearch @AstraZeneca
lvisa retweeted
🚀Upper GI oral abstracts #ESMO26 Day 1 summary results
1) Arcotatug tavatecan improved PFS in CLDN18.2+ G/GEJA in the 3L+ setting
2) SANO trial, OS at 5 years similar between active surveillance and surgery in patients with oesophageal cancer and a complete clinical response after nCR, despite more distant metastasis
3) Adding pembrolizumab to dCRT did not improve EFS in untreated unresectable esophageal or GEJ cancer with PD-L1 CPS ≥10
4) Daraxonrasib demonstrated consistent OS benefit in different RAS mutatin subgroups in RASolute-302
5) mKRAS-specific lymph node targeted amphiphile immunotherapy in PDAC did not met primary DFS endpoint.
6) Zani + CT +/- tisle keep OS benefit in at IA2 of HERIZON-GEA-01
7) Anbenitamab plus ChT improved OS in patients with HER2-positive GC/GEJC adenoca after previous trastuzumab
8) TQB2102 (HER2 bispecific antibody-drug conjugate) plus bemotrizumab and capecitabine demonstrates promising antitumor activity in 1L of advanced GC/GEJC
9) Dostarlimab in Pts with localized dMMR/MSI-H GEA led to a 62.5% 1y-cCR at the first interim analysis, enabling organ preservation.
10) FOLFIRI and Ram vs paclitaxel in taxan-pretreated GEA imporved PFS but no OS
11) Stage II–IIIB gastric cancer after D2 resection, four months of adjuvant XELOX was noninferior to six months for 3-year DFS
12) Adding durvalumab to dCRT in locally advanced esophagus carcinoma did not improve PFS
13) Adding SBRT to MFOLFIRINOX in high risk, borderline resectable or locally advanced pancreatic cancer mproved LRR and PFS
14) FGFR2b expressing GC/GEJ with co-existing FGFR2 amp may define a biologically distinct subset with potential sensitivity to bemarituzumab
#cancer #oncology #MedX #GI #gastrointestinal @OncoAlert
lvisa retweeted
Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
@Annals_Oncology
doi.org/10.1016/j.annonc.202…
👉get the latest updates
👉Biomarker testing (e.g. HER2, MSI, CLDN18.2, PD-L1) key
@myESMO @ASCO
lvisa retweeted
🚀Upper GI oral abstracts of #ESMO26 👇
✅Gastric/esophageal
✅Pancreatic
✅Hepatobiliary
✅NET/NEC
#cancer #oncology #MedX #GI #pancreatic #biliary #cholangiocarcinoma #liver #hepatocellular #gastric #esophageal #neuroendocrine @OncoAlert
lvisa retweeted
💜 Os recomeneamos este post, donde Pilar Navarro @PNavarro_Lab y nuestro colaborador, el Dr. José Yélamos, nos explican por qué apoyar la investigación contra el cáncer de páncreas es importante. Cada paso cuenta. 🏃♀️ #AcercamosLaMeta @HMar_research 👇
instagram.com/reel/DeH4HogIK…
lvisa retweeted
✨ Celebrating #WorldCancerResearchDay! We’re advancing #PancreaticCancer research to uncover molecular biomarkers 🧬, support earlier detection 🔎, and enable more targeted therapies 🎯.
Together, research brings hope. 💜💪 #CancerResearch
lvisa retweeted
💜 ¡Que no se te pase! El 13 de diciembre volvemos a correr por una buena causa en la XII Carrera de las Ciudades contra el Cáncer de Páncreas. ¿Ya tienes tu dorsal? 🏃♀️🏃♂️ Nos vemos en la salida. @Run4Pancreas #AcercamosLaMeta 💜👇
💜¡Vuelve a Barcelona la XII Carrera de las Ciudades contra el Cáncer de Páncreas!
📅13 de diciembre |🕙10 h |📍Fórum de Barcelona
Con el lema #AceleramosLaMeta, corre con @Run4Pancreas.
Inscríbete: carreracancerpancreas.es/cur…
¡Nos vemos en la salida!🏃♂️#carreradelasciudades
lvisa retweeted
🧬Atacar el tumor des de dins i que el sistema immunitari el reconegui.
🔬Un estudi de @HMar_research #HMRIB i @iibbcsi identifica en models animals la inhibició de PARP2 com una possible nova estratègia contra el càncer de pàncrees.
👉Més a @elperiodico: elperiodico.com/es/sanidad/2…
🩸 90% ctDNA NGS available vs 50% tissue NGS
🎯 83% concordance for ESCAT actionable alterations
⚡ 8 days ctDNA vs 27 days tissue
Expanding access to precision oncology
doi.org/10.1158/1078-0432.CC…
#LiquidBiopsy #BiliaryTractCancer
🩸 Can liquid biopsy bring precision medicine to more patients with biliary tract cancer?
Our study in @CCR_AACR—the largest real-world ctDNA cohort in advanced BTC to date (10,937 patients)—suggests it can.
More patients profiled.
More opportunities for precision oncology.
ALT https://doi.org/10.1158/1078-0432.CCR-26-0096 #LiquidBiopsy #BiliaryTractCancer
lvisa retweeted
After RAS inhibitors: what comes next in pancreatic cancer? clinicbarcelona.org/en/news/… via @hospitalclinic @MacarullaTeresa
lvisa retweeted
Lamentamos profundamente el fallecimiento del Dr. Laureano Fernández Cruz, referente de la cirugía pancreática a nivel nacional e internacional y MH de la #AEC. Su legado permanecerá siempre en nuestra especialidad. Nuestro más sentido pésame a familiares y amigos.
DEP
lvisa retweeted
🩸Una extracció de sang pot aportar informació molecular clau quan no hi ha prou teixit tumoral.
🌊Un estudi de l'@hospitaldelmar i l'@HMar_research (#HMRIB) confirma la utilitat de la biòpsia líquida en el càncer de vies biliars.
🔬El treball, publicat a 'Clinical Cancer Research', analitza 10.937 pacients i valida els resultats en 126 casos de nou hospitals, amb una concordança del 83% entre les mostres de sang i de teixit.
👩⚕️Hi han participat Laura Visa, @ClaraMontagut, Beatriz Bellosillo i Jordi Badia-Ramentol, en col·laboració amb #CIBERONC @CIBER_ISCIII i @GuardantHealth, amb participació de nou centres hospitalaris de l'Estat.
👉Consulta els resultats i el seu impacte: hospitaldelmar.cat/ca/notici…
#Biomarcadors #Genòmica #Recerca #Oncologia
lvisa retweeted
🩸A blood test can provide key molecular information when tumour tissue is insufficient.
🌊A study by @hospitaldelmar & @hmar_research (#HMRIB) confirms the usefulness of liquid biopsy in bile duct cancer.
🔬The study, published in 'Clinical Cancer Research', analysed 10,937 patients and validated the results in 126 new hospital cases. The study achieved 83% concordance between blood and tissue samples.
👩⚕️ The study involved Laura Visa, @claramontagut, Beatriz Bellosillo and Jordi Badia-Ramentol, in collaboration with #CIBERONC @ciber_isciii & @guardanthealth, with participation from new hospitals across the country.
👉View the results and their impact here: hospitaldelmar.cat/en/notici…
#Biomarkers #Genomics #Research #Oncology
lvisa retweeted
🩸¿Y si no hay suficiente tejido tumoral?
🧬Estudio liderado por @hmar_research #HMRIB @hospitaldelmar muestra 83% concordancia entre biopsia líquida y tejido en alteraciones del cáncer vías biliares
🗞️researchmar.net/noticias/135…
@claramontagut #CIBERONC @ciber_isciii @guardanthealth
lvisa retweeted
🩸Una extracción de sangre puede aportar información molecular clave cuando no hay bastante tejido tumoral.
🌊Un estudio del @hospitaldelmar y el @hmar_research (#HMRIB) confirma la utilidad de la biopsia líquida en el cáncer de vías biliares.
🔬El trabajo, publicado a 'Clinical Cancer Research', analiza 10.937 pacientes y valida los resultados en 126 casos de nuevo hospitales, con una concordancia del 83% entre las muestras de sangre y de tejido.
👩⚕️ Han participado Laura Visa, @claramontagut, Beatriz Bellosillo y Jordi Badia-Ramentol, en colaboración con #CIBERONC @ciber_isciii y @guardanthealth, con participación de nuevo centros hospitalarios del Estado.
👉Consulta los resultados y su impacto: hospitaldelmar.cat/es/notici…
#Biomarcadores #Genómica #Investigación #Oncología
lvisa retweeted
🚨 Can exercise help IO work better? New review on physical activity and the tumor immune microenvironment! 🏃🏻♂️
link.springer.com/article/10…
🫁 ↑ perfusion & oxygenation → ↓ hypoxia/acidosis
▪️ Macrophage repolarization + ↑ T/NK-cell infiltration & function
🎯 Preclinical data suggest greater sensitivity to PD-1/PD-L1 blockade
Maybe the immune system also benefits from a little training 🏃🏻♂️
@OncoAlert
@OncoReporte @myESMO @_SEOM
